In MGO-treated cells, YAP induction was associated with a decrease in protein levels of LATS1, a well-established negative regulator of YAP activity [32], whereas CML treatment failed to modulate LATS1 (Fig. 6c). The gene discussed is LATS1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.